Xeomin vs. Dysport vs. Daxxify: Which Neurotoxin Is Right for You?

Key Takeaways

• Xeomin, Dysport, and Daxxify are all botulinum toxin type A — the same mechanism, but different formulations that are not clinically interchangeable.
• Xeomin contains only the active 150 kDa neurotoxin with no accessory proteins; published literature supports that this reduces theoretical antigenic exposure compared with formulations that carry complexing proteins.
• Dysport carries accessory proteins and a molecular weight of 300–500 kDa; it spreads a bit wider and tends to kick in quickly, which suits certain treatment areas but is not typically where a new patient starts.
• Daxxify contains no accessory proteins and uses a proprietary stabilizing peptide (RTP004) instead of human serum albumin — and in Shannon’s practice, patients often notice a glowy quality to the skin afterward.
• The “right” neurotoxin is not about which brand is strongest; it is about matching formulation to your history, your anatomy, and your goals — which is exactly what a clinical consultation is for.

The brand name on the syringe matters less than the clinical reasoning behind the choice.

---

“I keep seeing Botox, Dysport, Xeomin, Daxxify — I have no idea if they’re the same thing or if one is actually better for me.”

You Googled it. You landed on brand marketing pages and SEO blogs that either champion one product or give the same hedged non-answer — “they all work, it depends on the injector!” — and you closed the tab more confused than when you opened it.

That answer is not wrong, exactly. But it leaves out the part that actually matters: why a clinician would choose one over another for your face, and what the real differences in formulation mean in practice. That is what this article is for.

What they all have in common — and where the comparison actually begins

All three are botulinum toxin type A. They work by temporarily blocking the nerve signal that tells a muscle to contract, which softens the overlying skin and reduces the appearance of dynamic lines — lines caused by movement, like the ones between your brows when you squint or across your forehead when you raise it.

That shared mechanism is where the similarity ends. The formulations differ in molecular weight, accessory protein content, excipients, and how the body can respond to them over time. A peer-reviewed review published in Dove Medical Press puts it plainly in its title: botulinum toxin type A products are not interchangeable.

Here is what the differences actually are.

Xeomin: the naked neurotoxin

Xeomin (incobotulinumtoxinA) contains the 150 kDa active neurotoxin and nothing else — no accessory proteins, no complexing proteins. The Vizient side-by-side comparison of FDA-approved botulinum toxin formulations confirms: Xeomin lists accessory proteins as absent.

Why does that matter? Every injected protein is a potential antigen — something the immune system can learn to recognize and mount a response against. Accessory proteins, also called neurotoxin accessory proteins (NAPs), play no therapeutic role once injected; their only relevant job at that point is as potential immune stimulants. A peer-reviewed analysis of complexing protein-free formulations and the implications of excipients for immunogenicity describes the reasoning: reducing the non-therapeutic protein load reduces the material available to provoke an immune response.

In practical terms: the concern is secondary nonresponse — a gradual loss of efficacy that can develop when the body builds neutralizing antibodies to repeated toxin injections. A 2024 review in Toxins on the non-interchangeability of botulinum neurotoxin products discusses differences in immunogenic potential across formulations, with the evidence base drawn largely from therapeutic (not purely aesthetic) use, where doses are substantially higher and given over many years.

One important note, and it belongs right here: at aesthetic dosing ranges, clinically meaningful immunogenicity is uncommon across all currently approved botulinum toxin type A products. The theoretical advantage of Xeomin’s protein profile is more relevant for patients who receive high, repeated doses — which is most true in therapeutic conditions like cervical dystonia, not in cosmetic treatment of forehead lines. But for a patient who will be treated every few months for years, the reasoning still holds.

This is why Xeomin has been in my toolkit since I began doing injectables, and why it stays there. It is the one I reach for most often, across most treatment areas.

Dysport: fast onset, wider spread

Dysport (abobotulinumtoxinA) carries accessory proteins and has a molecular weight of 300–500 kDa according to the Vizient comparison. Its excipients include human serum albumin and lactose.

Clinically, Dysport has a long track record and a reliable result profile. It tends to kick in quickly, and it has a slightly wider diffusion pattern than other toxins — meaning it can spread a bit more from the injection point. That is neither good nor bad in itself; it depends entirely on where you are injecting and what you are trying to accomplish. For large, flat muscle groups, wider spread can be an asset. For areas where precision matters most, it is something to account for.

Because of that spread profile, Dysport is not typically where I start with a new patient. Getting to know someone’s anatomy first — how their muscles move, how they respond — means starting with a formulation that gives me more control over placement. Once I know your face, Dysport can be exactly the right tool.

The FDA’s own prescribing label for Dysport notes, as it does for all therapeutic proteins, that there is a potential for immunogenicity — and that antibody formation rates are highly dependent on assay sensitivity and specificity, making cross-product comparisons difficult.

Daxxify: the newest, with a different stabilizing system

Daxxify (daxibotulinumtoxinA-lanm) came to market in 2022. Like Xeomin, it contains no accessory proteins — the Vizient comparison confirms this. What makes Daxxify structurally distinct is its stabilizing system: instead of human serum albumin (which every other FDA-approved botulinum toxin uses), Daxxify uses a proprietary excipient peptide called RTP004, described in a Neurology journal study as highly positively charged, binding to negatively charged surfaces on the core neurotoxin with high avidity.

That peptide is part of what Revance calls Peptide Exchange Technology. Something I have noticed in my own patients: after Daxxify, skin often takes on a glowy, shiny quality. I have not seen that effect formally attributed to the peptide system in the published literature, so I will not tell you it is proven — only that I see it often enough to mention, and that patients who notice it tend to like it.

Daxxify can also run heavy. It is a formulation I approach with intention, not as a default. Where it earns its place is in patients who have had inconsistent results with other toxins — people who feel like their treatments stopped working, or never worked quite right. The different stabilizing system and protein profile give us another clinical option when the usual formulations have not delivered what we expected.

What this means for your appointment

Here is the honest version of “it depends on the injector.”

Before I recommend any neurotoxin, I want to know: Have you been treated before, and with what? How long did the result last? Did you notice any change in how well it worked over time? Are there areas where you felt it spread more than you wanted, or not enough? What is your skin doing that you want to address — movement lines, jaw tension, a lip flip?

Your history, your anatomy, and your goals together answer the formulation question. Someone who has been receiving neurotoxin treatments for a decade with no issues can be treated differently than someone who is brand-new, or someone who is coming in because their last provider’s results were disappointing.

At Bloomsburg Med Spa, the consult comes first. I am not going to hand you a menu of brands and ask you to pick. My job is to understand what you are working with and choose accordingly — and to explain the reasoning in plain language so you leave knowing more than when you came in.

One more thing worth saying: if what you actually need is surgery — a brow lift, for example — I will tell you that. Neurotoxin is the right tool for dynamic lines and certain structural corrections. It is not the right tool for everything, and spending money on treatments that will not get you where you want to go is not something I am interested in doing.

FAQ

Are Xeomin, Dysport, and Daxxify just different names for Botox?

They are all botulinum toxin type A, so they work by the same mechanism — blocking the nerve signal that causes muscle contraction. But they are different formulations with different molecular weights, different protein profiles, and different excipients. A peer-reviewed review in Dove Medical Press describes them specifically as not interchangeable. Botox (onabotulinumtoxinA) is its own separate formulation as well.

Does one neurotoxin last longer than the others?

Duration varies by individual — your metabolism, the area treated, and the dose all play a role. Daxxify uses a different stabilizing peptide system than the other approved toxins, and duration has been a focus of its clinical program; a study published in Neurology examined daxibotulinumtoxinA in cervical dystonia, which is a therapeutic rather than cosmetic indication. What that means for your forehead specifically is a consultation question, not a number I would quote you from a brand page.

Can I develop a resistance to neurotoxins?

The immune system can produce neutralizing antibodies in response to repeated injections of botulinum toxin — this is called secondary nonresponse. Peer-reviewed reviews of botulinum toxin non-interchangeability discuss differences in immunogenic potential between formulations that carry accessory proteins and those that do not, with the evidence drawn largely from therapeutic settings involving high, repeated doses. At standard aesthetic dosing, meaningful immunogenicity is uncommon across all currently approved type A products, but it is a real consideration for patients who have been treated regularly over many years. It is also one of the things worth raising at a consultation if you have been treated for a long time.

Is one neurotoxin safer than the others?

All three are FDA-approved for aesthetic use. Each has its own safety profile, excipient list, and clinical evidence base. The FDA’s prescribing information for each product notes the potential for immunogenicity, as it does for all therapeutic proteins. “Safer” is not a blanket statement that applies across the board — it depends on your individual history, contraindications, and what you are being treated for. That assessment happens in a clinical consultation, not by comparing brand websites.

How do I know which one is right for me?

You probably do not know yet, and that is completely normal. The right formulation comes out of a conversation about your history with neurotoxins (if any), your anatomy, and what you are hoping to achieve. That is what the first appointment is for.

---

Ready to figure out which neurotoxin actually fits your goals? Book a consultation at Bloomsburg Med Spa and we will start from wherever you are.